Cargando…

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report

A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunizawa, Kyohei, Hoshino, Junichi, Mizuno, Hiroki, Suwabe, Tatsuya, Sumida, Keiichi, Kawada, Masahiro, Yamanouchi, Masayuki, Sekine, Akinari, Hayami, Noriko, Hiramatsu, Rikako, Hasegawa, Eiko, Sawa, Naoki, Takaichi, Kenmei, Shibata, Shigeru, Ubara, Yoshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903093/
https://www.ncbi.nlm.nih.gov/pubmed/29692992
http://dx.doi.org/10.1159/000487921
_version_ 1783314883591274496
author Kunizawa, Kyohei
Hoshino, Junichi
Mizuno, Hiroki
Suwabe, Tatsuya
Sumida, Keiichi
Kawada, Masahiro
Yamanouchi, Masayuki
Sekine, Akinari
Hayami, Noriko
Hiramatsu, Rikako
Hasegawa, Eiko
Sawa, Naoki
Takaichi, Kenmei
Shibata, Shigeru
Ubara, Yoshifumi
author_facet Kunizawa, Kyohei
Hoshino, Junichi
Mizuno, Hiroki
Suwabe, Tatsuya
Sumida, Keiichi
Kawada, Masahiro
Yamanouchi, Masayuki
Sekine, Akinari
Hayami, Noriko
Hiramatsu, Rikako
Hasegawa, Eiko
Sawa, Naoki
Takaichi, Kenmei
Shibata, Shigeru
Ubara, Yoshifumi
author_sort Kunizawa, Kyohei
collection PubMed
description A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8 months of tolvaptan therapy, hypokalemia-related muscle weakness became prominent, and hypertension became refractory. Finally, treatment with low-dose tolvaptan (30 mg/day) and high-dose spironolactone (100 mg/day) normalized serum potassium and the blood pressure. Tolvaptan can induce urinary excretion of potassium in patients with primary aldosteronism, and possible mechanisms are discussed.
format Online
Article
Text
id pubmed-5903093
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-59030932018-04-24 Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report Kunizawa, Kyohei Hoshino, Junichi Mizuno, Hiroki Suwabe, Tatsuya Sumida, Keiichi Kawada, Masahiro Yamanouchi, Masayuki Sekine, Akinari Hayami, Noriko Hiramatsu, Rikako Hasegawa, Eiko Sawa, Naoki Takaichi, Kenmei Shibata, Shigeru Ubara, Yoshifumi Case Rep Nephrol Dial Case Report A 59-year-old Japanese woman was admitted for evaluation of muscle weakness. Autosomal dominant polycystic kidney disease had been diagnosed at the age of 47 years, followed by primary aldosteronism at 53 years. At the age of 58, tolvaptan was started (60 mg/day) to treat her renal disease. After 8 months of tolvaptan therapy, hypokalemia-related muscle weakness became prominent, and hypertension became refractory. Finally, treatment with low-dose tolvaptan (30 mg/day) and high-dose spironolactone (100 mg/day) normalized serum potassium and the blood pressure. Tolvaptan can induce urinary excretion of potassium in patients with primary aldosteronism, and possible mechanisms are discussed. S. Karger AG 2018-03-28 /pmc/articles/PMC5903093/ /pubmed/29692992 http://dx.doi.org/10.1159/000487921 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kunizawa, Kyohei
Hoshino, Junichi
Mizuno, Hiroki
Suwabe, Tatsuya
Sumida, Keiichi
Kawada, Masahiro
Yamanouchi, Masayuki
Sekine, Akinari
Hayami, Noriko
Hiramatsu, Rikako
Hasegawa, Eiko
Sawa, Naoki
Takaichi, Kenmei
Shibata, Shigeru
Ubara, Yoshifumi
Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title_full Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title_fullStr Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title_full_unstemmed Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title_short Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
title_sort tolvaptan for primary aldosteronism and autosomal dominant polycystic kidney disease: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903093/
https://www.ncbi.nlm.nih.gov/pubmed/29692992
http://dx.doi.org/10.1159/000487921
work_keys_str_mv AT kunizawakyohei tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT hoshinojunichi tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT mizunohiroki tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT suwabetatsuya tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT sumidakeiichi tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT kawadamasahiro tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT yamanouchimasayuki tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT sekineakinari tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT hayaminoriko tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT hiramatsurikako tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT hasegawaeiko tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT sawanaoki tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT takaichikenmei tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT shibatashigeru tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport
AT ubarayoshifumi tolvaptanforprimaryaldosteronismandautosomaldominantpolycystickidneydiseaseacasereport